Antibody to hepatitis B core antigen as a screening test for occult hepatitis B virus infection in Egyptian chronic hepatitis C patients

Journal of Gastroenterology

Volumn 44, Issue 4, 2009, Pages 359-364

  El Sherif, Assem ^a   Abou Shady, Mohamed ^a   Abou Zeid, Hany ^a   Elwassief, Ahmed ^a   Elbahrawy, Ashraf ^b   Ueda, Yoshihide ^b   Chiba, Tsutomu ^b   Hosney, Abdel Moneim ^a  

^a AL AZHAR UNIVERSITY   (Egypt)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Anti HBc; Chronic HCV; Egyptian patients; Occult HBV

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; PROTHROMBIN; VIRUS DNA;

ADULT; ANTIBODY DETECTION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; ECHOGRAPHY; EGYPT; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SCREENING TEST;

ADULT; DNA, VIRAL; EGYPT; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREVALENCE; SEVERITY OF ILLNESS INDEX;

EID: 65049083565     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-009-0020-3     Document Type: Article

References (33)

1. Lavanchy D, McMahon B. Worldwide prevalence and prevention of hepatitis C. In: Liang TJ, Hoofnagle JH, editors. Hepatitis C. San Diego: Academic Press; 2000. p. 185-202.
2. World Health Organization (1995) Inter-country workshop on the prevention and control of Viral Hepatitis. Cairo, Egypt, 16-20 April. WHO regional Office, EMRO. EM/EPD/92/E.
3. Ray SC, Arthur RR, Carella A, Bukh J, Thomas DL. Genetic epidemiology of hepatitis C virus throughout Egypt. J Infect Dis. 2000;182:698-707.
4. Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal A, Zaid MA, et al. Genotypes and phylogenetic characterization of hepatitis B and delta viruses in Egypt. J Med Virol. 2003;70:529-36.
5. Marusawa H, Osaki Y, Kimura T, Ito K, Yamashita Y, Eguchi T, et al. High prevalence of anti-hepatitis B virus serological markers in patients with hepatitis C virus related chronic liver disease in Japan. Gut. 1999;45:284-8.
6. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely "occult"? Hepatology. 2001;34:194-203.
7. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med. 1999;341:22-6.
8. Fukuda R, Ishimura N, Niigaki M, Hamamoto S, Satoh S, Tanaka S. Serologically silent hepatitis B virus coinfection in patients with hepatitis C virus-associated chronic liver disease: Clinical and virological significance. J Med Virol. 1999;58:201-7.
9. Georgiadou SP, Zachou K, Rigopoulou E, Liaskos C, Mina P, Gerovasilis F, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat. 2004;11:358-65.
10. Sagnelli E, Coppola N, Scolastico C, Ar Mogavero, Filippini P, Piccinino F. HCV genotype and "silent" HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol. 2001;64:350-5.
11. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis. 2002;2:479-86.
12. Paterlini P, Gerken G, Nakajima E, Terre S, D'Errico A, Grigioni W, et al. Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med. 1990;323:80-5.
13. Donato F, Gelatti U, Limina RM, Fattovich G. Southern Europe as an example of interaction between various environmental factors: A systematic review of the epidemiologic evidence. Oncogene. 2006;25:3756-70.
14. Huo TI, Wu JC, Lee PC, Chau GY, Lui WY, Tsay SH, et al. Sero-clearance of hepatitis B surface antigen in chronic carriers does not necessarily imply a good prognosis. Hepatology. 1998;28:231-6.
15. Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: A prospective study. Ann Intern Med. 2007;146:649-56.
16. Mulrooney-Cousins PM, Michalak TI. Persistent occult hepatitis B virus infection: Experimental findings and clinical implications. World J Gastroenterol. 2007;13:5682-6.
17. Jilg W, Sieger E, Zachoval R, Schatzl H. Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol. 1995;23:14-20.
18. Weber B, Berger A. Molecular detection of hepatitis B virus: Recent development. J Lab Med. 2005;29:33-43.
19. Abdel-Wahab MF, Esmat G, Millad M, Abdel-Razek S, Strickland GT. Characteristic sonographic pattern of schistosomal hepatic fibrosis. Am J trop Med Hyg. 1989;40:72-6.
20. Chemin I, Zoulim F, Merle P, Arkhis A, Chivallier M, Kay A, et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol. 2001;34:447-54.
21. Brechot C. Pathogenesis of hepatitis B virus related hepatocellular carcinoma: Old and new paradigms. Gastroenterology. 2004;127:S56-61.
22. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol. 2007;46:160-70.
23. Sheu JC, Huang GT, Shin LN, Lee WC, Chou HC, Wang JT, et al. Hepatitis C and B viruses in hepatitis B surface antigen-negative hepatocellular carcinoma. Gastroenterology. 1992;103:1322-7.
24. Brechot C, Minami M, De Mitri S, Paterlini P. Hepatitis B and C viruses in hepatitis B surface antigen negative hepatocellular carcinoma patients. Princess Takamatsu Symp. 1995;25:199-209.
25. Koike K. Co-infection of HBV with HCV and a possible role of HBV DNA in hepatocarcinogenesis. Nippon Rinsho. 1999;57:213-9.
26. Tamori A, Nishiguchi S, Kubo S, Enomoto M, Koh N, Takeda T, et al. Sequencing of human-viral DNA junctions in hepatocellular carcinoma from patients with HCV and occult HBV infection. J Med Virol. 2003;69:475-81.
27. Mrani S, Chemin I, Menouar K, Guillaud O, Pradat P, Borghi G, et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol. 2007;79:1075-81.
28. El-Zayadi AR, Ibrahim EH, Badran HM, Saeid A, Moneib NA, Shemis MA, et al. Anti-HBc screening in Egyptian blood donors reduces the risk of hepatitis B virus transmission. Transfus Med. 2008;18:55-61.
29. El-Sherif A, Abou-Shady M, Al-Hiatmy M, Al-Bahrawy A, Motawea E. Screening for hepatitis B virus infection in Egyptian blood donors negative for hepatitis B surface antigen. Hepatol Int. 2007;1:469-70.
30. Raimondo G, Navarra G, Mondello S, Costantino L, Colloredo G, Cucinotta E, et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol. 2008;48:743-6.
31. Marusawa H, Uemoto S, Hijikata M, Ueda Y, Tanaka K, Shimotohno K, et al. Latent hepatitis B virus infection in healthy individual with antibody to hepatitis B core antigen. Hepatology. 2000;31:488-95.
32. Okada S, Sato T, Okusaka T, Ishii H, Ikeda M, Nakasuka H, et al. Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease. Br J Cancer. 1998;77:2028-31.
33. Imazeki F, Yokosuka O, Fukai K, Hiraide A, Saisho H. Significance of prior hepatitis B virus infection in the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci. 2003;48:1786-92.